Key points
- The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
- These recommendations become official CDC policy once adopted by CDC's Director.
- Learn about current and historical ACIP recommendations for Respiratory Syncytial Virus (RSV) immunizations.
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the CDC regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the CDC Director and, if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT RSV vaccine immunizations
- MMWR; August 15, 2024 / 73(32);696-702
Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version- See also:
- Respiratory Syncytial Virus (RSV) Vaccine Safety
- FDA self-controlled case series GBS update
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Moderna mRNA RSV Vaccine (mResvia) in older adults
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults
- ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
- ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease
- Respiratory Syncytial Virus (RSV) Vaccine Safety
- See also:
- MMWR; October 13, 2023 / 72(41);1115–1122
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version
- MMWR; August 25, 2023 / 72(34);920–925
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version- See also:
- GRADE: Nirsevimab, Season 1 | CDC
- ACIP Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season | CDC
- GRADE: Nirsevimab, Season 2 | CDC
- ACIP Evidence to Recommendations for Use of Nirsevimab in Children 8–19 months of age with increased risk of severe disease entering their second RSV season | CDC
- GRADE: Nirsevimab, Season 1 | CDC
- See also:
ARCHIVED RSV immunization publications
For your convenience, these archived publications can be used for historical and research purposes.
- MMWR; July 21, 2023;72(29);793–801
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
Print version- See also:
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY) | CDC
- ACIP Evidence to Recommendations for Use of GSK Adjuvanted RSVPreF3 Vaccine (AREXVY) in Adults Ages 60 and Older | CDC
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer RSVpreF Vaccine (ABRYSVO) | CDC
- ACIP Evidence to Recommendations for Use of Pfizer Bivalent RSVpreF Vaccine (ABRSYVO) in Older Adults | CDC
- Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): GSK RSVPreF3 Vaccine (AREXVY) | CDC
- See also: